Loading
A phase 1/2 trial of Pembrolizumab, Pemetrexed, Gemcitabine in non-small-cell lung cancer, run by Inhibrx Biosciences, Inc, now recruiting.
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) is a phase 1/2 interventional study registered as NCT04198766 by Inhibrx Biosciences, Inc, with 340 participants planned, started 2019-12-10 and due to reach its primary completion in 2033-07. Interventions recorded: INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg, Carboplatin AUC-5, Carboplatin AUC-6. Conditions listed: Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pemetrexed, Pembrolizumab, Non-small-cell lung cancer.
Shares Pemetrexed, Pembrolizumab, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares Pemetrexed, Gemcitabine, Pembrolizumab, Immune checkpoint inhibitors.
Shares Pemetrexed, Pembrolizumab, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares Pemetrexed, Pembrolizumab, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares Pemetrexed, Pembrolizumab, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares Pemetrexed, Pembrolizumab, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares Pemetrexed, Gemcitabine, Pembrolizumab, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/